A5042884943- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- SARS-CoV-2 detection and testing
- Polyomavirus and related diseases
- Parvovirus B19 Infection Studies
- COVID-19 Impact on Reproduction
- Animal Virus Infections Studies
- Complement system in diseases
- Vaccine Coverage and Hesitancy
- Renal Transplantation Outcomes and Treatments
- Cytomegalovirus and herpesvirus research
- Herpesvirus Infections and Treatments
- Cerebrospinal fluid and hydrocephalus
- Health, Medicine and Society
- Viral Infections and Immunology Research
- Neurological Complications and Syndromes
- Muscle and Compartmental Disorders
- Healthcare Systems and Practices
- Immune responses and vaccinations
- COVID-19 and healthcare impacts
- Full-Duplex Wireless Communications
- Infection Control and Ventilation
- Heparin-Induced Thrombocytopenia and Thrombosis
- Poxvirus research and outbreaks
Université de Strasbourg
2019-2025
Inserm
2019-2025
Fédération Hospitalo-Universitaire, Paris Center for Microbiome Medicine
2020-2024
Hôpitaux Universitaires de Strasbourg
2019-2024
Immuno-Rhumathologie moléculaire
2020-2022
University of Abou Bekr Belkaïd
2021
Hôpital Civil, Strasbourg
2021
Institut de Virologie
2020
Université Lille Nord de France
2012
Brian J. Boyarsky, MD; William A. Werbel, Robin K. Avery, Aaron R. Tobian, MD, PhD; Allan B. Massie, Dorry L. Segev, Jacqueline M. Garonzik-Wang, PhD
There are no studies which have compared the risk of severe COVID-19 and related mortality between transplant recipients nontransplant patients. We enrolled two groups patients hospitalized for COVID-19, that is, kidney (KTR) from French Registry Solid Organ Transplant (n = 306) a single-center cohort 795). An analysis was performed among subgroups matched age factors or mortality. Severe defined as admission (or transfer) to an intensive care unit, need mechanical ventilation, death. were...
Background and purpose Neurological manifestations in coronavirus disease (COVID)‐2019 may adversely affect clinical outcomes. Severe COVID‐19 uremia are risk factors for neurological complications. However, the lack of insight into their pathogenesis, particularly with respect to role cytokine release syndrome (CRS), is currently hampering effective therapeutic interventions. The aims this study were describe patients gain pathophysiological insights CRS. Methods In longitudinal study, we...
LettersMarch 2022Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case SeriesFREESophie Caillard, MD, PhD, Olivier Thaunat, Ilies Benotmane, Christophe Masset, Gilles Blancho, PhDSophie PhDDepartment of Nephrology and Transplantation, University Hospitals Strasbourg, INSERM Unit 1109, France, Transplantation Clinical Immunology, Hospices Civils de Lyon, Claude Bernard Lyon 1 University, 1111, MDDepartment MDInstitut Urologie Néphrologie,...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread widely, causing disease 2019 (COVID-19) and significant mortality. However, data on viral loads antibody kinetics in immunocompromised populations are lacking. We aimed to determine nasopharyngeal plasma via reverse transcription-polymerase chain reaction SARS-CoV-2 serology enzyme-linked immunosorbent assay study their association with severe forms of COVID-19 death kidney transplant recipients. In this study, we...
Transplant recipients, who receive therapeutic immunosuppression to prevent graft rejection, are characterized by high coronavirus disease 2019 (COVID-19)-related mortality and defective response vaccines. We observed that previous infection with severe acute respiratory syndrome 2 (SARS-CoV-2), but not the standard two-dose regimen of vaccination, provided protection against symptomatic COVID-19 in kidney transplant recipients. therefore compared cellular humoral immune responses these two...
It remains unclear whether physicians should accept transplantation offers for candidates with a positive SARS-CoV-2 reverse transcription polymerase chain reaction test due to the potential risk of severe infection after initiating immunosuppressive therapy. A multicenter observational study was conducted in 19 French solid organ units. Patients on waiting list liver or kidney transplants who had nasopharyngeal swab at time were recorded. Sixty-five patients included. The recipients...
Abstract Background Neurological manifestations are common in patients with coronavirus disease 2019 (COVID-19), but little is known about pathophysiological mechanisms. In this single-center study, we examined neurological 58 patients, including cerebrospinal fluid (CSF) analysis and neuroimaging findings. Methods The study included COVID-19 whom severe acute respiratory syndrome 2 (SARS-CoV-2) reverse-transcription polymerase chain reaction screening on CSF were performed. Clinical,...
Data on coronavirus disease 2019 (COVID-19) in immunocompromised kidney transplant recipients (KTR) remain scanty. Although markers of inflammation, cardiac injury, and coagulopathy have been previously associated with mortality the general population patients COVID-19, their prognostic impact amongst KTR severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has not specifically investigated.We conducted a cohort study 49 who presented COVID-19. Clinical laboratory risk...
BK virus (BKV) replication occurs frequently in kidney transplant recipients (KTR), potentially leading to BKV-associated nephropathy (BKVAN) and graft loss. Patients with high titers of BKV-neutralizing antibodies (NAbs) are protected against BKV replication, intravenous immunoglobulin (IVIg) infusion can increase NAb titers. We investigated whether early IVIg administration prevents patients low (<4 log10 the BKV-specific genotype). Based on day transplantation, KTR followed Strasbourg...
The exact duration of viable SARS-CoV-2 shedding in kidney transplant recipients (KTRs) remains unclear. Here, we retrospectively investigated this issue using cell cultures RT-PCR-positive nasopharyngeal samples (n = 40) obtained from 16 KTRs with symptomatic COVID-19 up to 39 days symptom onset. A length >3 weeks the onset symptoms was identified four (25%). These results suggest that a significant proportion can shed for at least 3 weeks, which may favor emergence new variants. Based on...
Decreased immunosuppression has been proposed for kidney transplant recipients infected with coronavirus disease 2019 (COVID-19), but the impact on alloreactive immune response during and after infection poorly investigated. We evaluated occurrence of antihuman leukocyte antigen (HLA) donor-specific antibodies (DSAs) (post-COVID-19) rejection episodes COVID-19 particular focus modulation.Kidney from 2 French institutions had anti-HLA antibody screening before COVID-19. Management...
Abstract Transplant recipients display poor responses to SARS‐CoV‐2 mRNA vaccines. In this retrospective study, we investigate torque teno virus (TTV) viral load (VL), a ubiquitous reflecting global immune response levels, as predictive factor of vaccine in kidney transplant (KTR). Four hundred and fifty‐nine KTR having received two doses were enrolled, 241 them subsequently third dose. Antireceptor‐binding domain (RBD) IgG was assessed after each dose TTV VL measured pre‐vaccine samples....
Abstract Background Immunocompromised patients account for a large proportion of COVID-19 hospitalizations and deaths, even in the most recent periods, despite having received several vaccine doses. Monoclonal antibodies effectively prevented general population randomized control trials immunocompromised real-world studies. Unfortunately, emergence new variants precluded their use. Sipavibart (AZD3152) is an investigational long-acting monoclonal antibody designed to provide broad coverage...